Prognosis of metastatic melanoma is changing due to advances in immunotherapy and targeted therapy. However, management of patients with brain metastases in day-to-day practice continues to be a challenge.
Case Report
We describe a 40-year-old woman diagnosed with symptomatic brain metastases from cutaneous melanoma and Eastern Cooperative Oncology Group 3. She was treated, off label, with BRAF inhibitor (dabrafenib) + MEK inhibitor (trametinib) and radiotherapy. There was significant, long-lasting, response (17 months), no clinically relevant toxicity, and clear improvement in quality of life.
Conclusions
This case is an example of real-life application of advances in targeted therapy.
Osella-AbateSRiberoSSanlorenzoMRisk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer. 2015; 136 (10): 2453–2457.
2.
LarkinJAsciertoPADrénoBCombined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371 (20): 1867–1876.
3.
RobertCKaraszewskaBSchachterJImproved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372 (1): 30–39.
4.
AsciertoPASimeoneESileniVCSequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of ipilimumab expanded access programme (EAP). J Clin Oncol. 2013; 319035.
5.
Study to evaluate treatment of dabrafenib plus trametinib in subjects with BRAF mutation-positive melanoma that has metastasized to the brain: 2014. Available at: https://clinicaltrials.gov/ Accessed November 1, 2014.
6.
ChapmanPBHauschildARobertC>BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364 (26): 2507–2516.
7.
HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380 (9839): 358–365.
8.
DummerRGoldingerSMTurtschiCPVemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014; 50 (3): 611–621.
9.
LongGVTrefzerUDaviesMADabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13 (11): 1087–1095.
10.
HauswaldHDittmarJOHabermehlDEfficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol. 2012; 7 (1): 130.
11.
Vemurafenib combined with whole brain radiation therapy or radiosurgery in patients with BRAF mutation-positive melanoma and brain metastases: 2014. Available at: https://clinicaltrials.gov/ Accessed November 1, 2014.
